Oral Cancer Diagnostics Market

Cancer is generally defined as the uncontrollable growth of cells which invade and cause damage to surrounding tissues.

Oral cancer specifically, are painful lumps, or growth in the mouth that affect its surrounding tissues. Oral cancer is a broad category and includes a number of conditions such as cancers of lips, tongue, cheeks, hard and soft palate, the floor of the mouth, pharynx, and sinuses. Oral cancer is treatable but can be life-threatening if not diagnosed early and treated properly.

Diagnosis of oral cancer is extremely crucial as the treatment of the disease is dependent on the stage of cancer since earlier the diagnosis, easier to manage the cancerous growth. There are a number of diagnostic tests for the diagnosis of oral cancer. Most commonly used methods include computed tomography (CT), magnetic resonance imaging (MRI), X-ray, and ultrasonography.

Major factors characterizing the market growth are the increase in population suffering from oral cancer, effective diagnostic aids in the detection of oral cancer coupled with the increase in research & development and rise in risk factors leading to oral cancers. On the other hand, the shortage of trained professionals and the inability of healthcare organizations to purchase expensive imaging systems are likely to restrict market growth during the assessment period.

The global oral cancer diagnostics market has been segmented based on indication, diagnosis type, end user, and region. The global oral cancer diagnostics market was valued at USD 4,909.60 million in 2018, is estimated to grow at USD 7,367.90 million by 2024. In 2018, the Americas accounted for the largest market share of 42.40% with a market value of USD 2,081.67 million, followed by Europe with a market value of USD 1,382.05 million in 2018.

Based on indication, the oral squamous cell carcinoma segment accounted for the largest market share of 89.02% in 2018, with a market value of USD 4,370.55 million, which is projected to register a CAGR of 21.13% during the forecast period.

Based on diagnosis type, the computed tomography (CT) segment accounted for the largest market share of 30.07% in 2018, with a market value of USD 1,476.13 million, which is projected to register a CAGR of 7.16% during the forecast period.

On the basis of end user, the hospitals and clinics segment dominated the market and accounted for a share of 45.81% in 2018, with a market value of USD 2,249.08 million, which is anticipated to register a CAGR of 7.56% during the forecast period.